NKX2-1 and bladder transitional cell carcinoma: Although NKX2-1 expression levels were very low in these cancers, its expression levels were significantly different in bladder urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), HPV-positive HNSC and HPV-negative HNSC, kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), SKCM-metastasis, and uterine corpus endometrial carcinoma (UCEC) (Fig. 1A).